TY - JOUR
T1 - Comparing intracerebral hemorrhages associated with direct oral anticoagulants or warfarin
AU - Kurogi, Ryota
AU - Nishimura, Kunihiro
AU - Nakai, Michikazu
AU - Kada, Akiko
AU - Kamitani, Satoru
AU - Nakagawara, Jyoji
AU - Toyoda, Kazunori
AU - Ogasawara, Kuniaki
AU - Ono, Junichi
AU - Shiokawa, Yoshiaki
AU - Aruga, Toru
AU - Miyachi, Shigeru
AU - Nagata, Izumi
AU - Matsuda, Shinya
AU - Yoshimura, Shinichi
AU - Okuchi, Kazuo
AU - Suzuki, Akifumi
AU - Nakamura, Fumiaki
AU - Onozuka, Daisuke
AU - Ido, Keisuke
AU - Kurogi, Ai
AU - Mukae, Nobutaka
AU - Nishimura, Ataru
AU - Arimura, Koichi
AU - Kitazono, Takanari
AU - Hagihara, Akihito
AU - Iihara, Koji
N1 - Funding Information:
This study was funded by the Japanese government and the Japan Society for the Promotion of Science. Some authors report receiving honoraria, funding, and advisory committee appointments from various pharmaceutical companies. Go to Neurology.org/N for full disclosures.
Funding Information:
This work was supported by Grants-in-Aid from the Japanese Ministry of Health, Labour and Welfare and a KAKENHI grant (25293314; principal investigator: Koji Iihara) from the Japan Society for the Promotion of Science. This research is partially supported by the Practical Research Project for Life-Style related Diseases including Cardiovascular Diseases and Diabetes Mellitus managed by the Japan Agency for Medical Research and Development. The funding sources had no role in the study design, data collection and analysis, manuscript preparation, or decision to publish.
Funding Information:
R. Kurogi reports no disclosures relevant to the manuscript. K. Nishimura reports receiving lecture fees from Bristol-Myers Squibb. M. Nakai, A. Kada, S. Kamitani, and J. Nakagawara report no disclosures relevant to the manuscript. K. Toyoda reports receiving honoraria for lectures from Bayer, Daiichi-Sankyo, Boehringer-Ingelheim, and Bristol-Myers Squibb. K. Ogasawara reports receiving grants from Nihon Medi-Physics and Bristol-Myers Squibb. J. Ono, Y. Shiokawa, T. Aruga, and S. Miyachi report no disclosures relevant to the manuscript. I. Nagata reports receiving honoraria for lectures from Bristol-Myers Squibb. S. Matsuda reports receiving honoraria for lectures from Chugai Pharmaceutical. S. Yoshimura reports receiving grants from Shionogi & Co., Terumo, Takeda, and Bristol-Meyers Squibb and honoraria for lectures from Mitsubishi Tanabe Pharma, Sanofi, Bristol-Myers Squibb, Boehringer-Ingelheim, Otsuka Pharmaceutical, Bayer, Daiichi Sankyo, and Pfizer. K. Okuchi reports no disclosures relevant to the manuscript. A. Suzuki is a member of the medical advisory committee to the Akita Pilot Study undertaken by Bayer. F. Nakamura reports receiving grants from Asahi Kasei. D. Onozuka, K. Ido, A. Kurogi, N. Mukae, A. Nishimura, and K. Arimura report no disclosures relevant to the manuscript. T. Kitazono reports receiving speaker fees from Bayer Yakuhin and Daiichi Sankyo, consulting fees from Chugai Pharmaceutical, and grants from Mitsubishi Tanabe Pharma, Takeda Pharmaceutical, Eizai, Merck Sharp & Dohme, Astellas Pharma, Daiichi Sankyo, and Chugai Pharmaceutical. A. Hagihara reports no disclosures relevant to the manuscript. K. Iihara reports receiving grants from Otsuka Pharmaceutical, Nihon Medi-Physics, and AstraZeneca. Go to Neurology.org/ N for full disclosures.
Publisher Copyright:
© 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
PY - 2018/3/27
Y1 - 2018/3/27
N2 - Objectives This cross-sectional survey explored the characteristics and outcomes of direct oral anticoagulant (DOAC)-associated nontraumatic intracerebral hemorrhages (ICHs) by analyzing a large nationwide Japanese discharge database. Methods We analyzed data from 2,245 patients who experienced ICHs while taking anticoagulants (DOAC: 227; warfarin: 2,018) and were urgently hospitalized at 621 institutions in Japan between April 2010 and March 2015. We compared the DOAC-and warfarin-treated patients based on their backgrounds, ICH severities, antiplatelet therapies at admission, hematoma removal surgeries, reversal agents, mortality rates, and modified Rankin Scale scores at discharge. Results DOAC-associated ICHs were less likely to cause moderately or severely impaired consciousness (DOAC-associated ICHs: 31.3%; warfarin-associated ICHs: 39.4%; p = 0.002) or require surgical removal (DOAC-associated ICHs: 5.3%; warfarin-associated ICHs: 9.9%; p = 0.024) in the univariate analysis. Propensity score analysis revealed that patients with DOAC-associated ICHs also exhibited lower mortality rates within 1 day (odds ratio [OR] 4.96, p = 0.005), within 7 days (OR 2.29, p = 0.037), and during hospitalization (OR 1.96, p = 0.039). Conclusions This nationwide study revealed that DOAC-treated patients had less severe ICHs and lower mortality rates than did warfarin-treated patients, probably due to milder hemorrhages at admission and lower hematoma expansion frequencies.
AB - Objectives This cross-sectional survey explored the characteristics and outcomes of direct oral anticoagulant (DOAC)-associated nontraumatic intracerebral hemorrhages (ICHs) by analyzing a large nationwide Japanese discharge database. Methods We analyzed data from 2,245 patients who experienced ICHs while taking anticoagulants (DOAC: 227; warfarin: 2,018) and were urgently hospitalized at 621 institutions in Japan between April 2010 and March 2015. We compared the DOAC-and warfarin-treated patients based on their backgrounds, ICH severities, antiplatelet therapies at admission, hematoma removal surgeries, reversal agents, mortality rates, and modified Rankin Scale scores at discharge. Results DOAC-associated ICHs were less likely to cause moderately or severely impaired consciousness (DOAC-associated ICHs: 31.3%; warfarin-associated ICHs: 39.4%; p = 0.002) or require surgical removal (DOAC-associated ICHs: 5.3%; warfarin-associated ICHs: 9.9%; p = 0.024) in the univariate analysis. Propensity score analysis revealed that patients with DOAC-associated ICHs also exhibited lower mortality rates within 1 day (odds ratio [OR] 4.96, p = 0.005), within 7 days (OR 2.29, p = 0.037), and during hospitalization (OR 1.96, p = 0.039). Conclusions This nationwide study revealed that DOAC-treated patients had less severe ICHs and lower mortality rates than did warfarin-treated patients, probably due to milder hemorrhages at admission and lower hematoma expansion frequencies.
UR - http://www.scopus.com/inward/record.url?scp=85051966518&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051966518&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000005207
DO - 10.1212/WNL.0000000000005207
M3 - Article
AN - SCOPUS:85051966518
SN - 0028-3878
VL - 90
SP - e1143-e1149
JO - Neurology
JF - Neurology
IS - 13
ER -